CLDN3 and neoplasm: However, in the HCT116 and SNU-5 models with high expression of EpCAM but low expression of CLDN3, the anti-tumor activity of BsADC 3 was close to EpCAM monovalent ADC, significantly lower than that of the EpCAM parental monoclonal ADC (Fig. 6C and D).